http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2006098987-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_db7d76fca6639dd606671bfc5d493f46 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_13a7ac0e215a10ef98bce7136c7a35be http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_864074bd0fb7d522a7259a41a3871cb7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ed28726de9f916f355f8adc331e736b8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4e1ca77ee67ee5e1e84c78b7b1977c57 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-515 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-567 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate | 2006-03-09^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c6830af9bdb2766b039187473ad4f970 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_15c862cec15a38ca70132eca90c4170b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_53d644393630e9319f9e445e4e3d0376 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8f4c850051d2a0603b1acc52b18a44da |
| publicationDate | 2006-09-21^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2006098987-A2 |
| titleOfInvention | Methods of inhibiting angiogenesis and tumor development |
| abstract | The invention provides methods for identifying genes and proteins modulated by an antagonist. The antagonist can be to a cryptic epitope of an ECM component that specifically binds to the ECM component or an antagonist of αvβ3 that inhibits binding of αvβ3 to an ECM component. It additionally provides methods for using the products of the identified genes, or for using the identified proteins, for inhibiting angiogenesis, tumor metastasis, and other tumor developmental processes, including cell migration, cell adhesion, cell proliferation, and tumor growth and for treating angiogenesis-dependent conditions. The present invention relates to antagonists of cryptic epitopes of ECM components, wherein binding of these antagonists to cryptic epitopes of ECM components results in modulation of the expression of IGFBP-4, TSP-I, Id-I, p27KIP or p21CIP. The present invention relates to antagonists of αvβ3, wherein binding of these antagonists to αvβ3 results in modulation of the expression of IGFBP- 4 or TSP-I. The present invention also relates to methods of using these antagonists for inhibiting angiogenesis, tumor metastasis, and other tumor development processes as well as for treating angiogenesis-dependent conditions. The invention provides compositions comprising IGFBP-4 and methods for inhibiting angiogenesis and tumor development processes, and for treating angiogenesis-dependent conditions, using an insulin growth factor binding protein, IGFBP-4. |
| priorityDate | 2005-03-11^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Showing number of triples: 1 to 867 of 867.